Total
0
Shares
Cynata Therapeutics (ASX:CYP) - Managing Director & CEO, Dr Ross Macdonald - The Market Herald
Managing Director & CEO, Dr Ross Macdonald
Sourced: Cynata Therapeutics
  • Biotech company Cynata Therapeutics (CYP) has received positive results for its Cymerus stem cell treatment in a preclinical heart attack model
  • The study in rats showed enhanced recoveries in the subjects administered Cynata's mesenchymal stem cell (MSC) treatment
  • An earlier study by the same independent team had already shown Cynata's MSCs improved cardiac function after a heart attack
  • The latest results help to explain the mechanism for the superior therapeutic effects of Cymerus MSCs compared to conventional bone marrow MSCs
  • Once the data has been peer reviewed, Cynata will determine the next steps in the clinical development of the Cymerus treatment
  • Cynata Therapeutics is trading 1.44 per cent lower at $1.02.5

Cynata Therapeutics (CYP) has received positive results for its Cymerus stem cell treatment in a preclinical heart attack model.

The study in rats showed enhanced recoveries in the subjects administered Cynata's mesenchymal stem cell (MSC) treatment. The study compared Cynata’s Cymerus MSCs to conventional bone marrow MSCs (BM-MSCs) and a placebo.

The results

The study showed the rats administered with Cynata's MSCs experienced enhanced blood vessel generation, which is a key element in recovery after heart attacks.

Breaking the results down further, Cynata's treatment doubled the development of new blood capillaries and provided a three-fold increase in the growth of small blood vessels (arterioles) as compared to the placebo group.

Subjects also released higher levels of molecules known to be involved in the stimulation of new blood vessel growth.

The study was conducted by a team led by Associate Professor James Chong at the Westmead Institute for Medical Research in Sydney.

An earlier study by the same team had already shown Cynata's MSCs improved cardiac function after a heart attack.

The latest results help to explain the mechanism for the superior therapeutic effects of Cymerus MSCs compared to conventional BM-MSCs.

The results will be submitted for peer review.

Cynata Chief Operating Officer Dr Kilian Kelly says the study has been a positive step in the clinical evaluation of the Cymerus treatment.

"With the benefit of this further data we are now able to better understand the beneficial effects of our Cymerus MSCs in this model of heart attack," Dr Kelly said.

"It is particularly notable that the latest results are consistent with the greater benefit demonstrated by Cymerus MSCs over BM-MSCs in the earlier studies of heart function," he continued.

"Given the scalability and consistency advantages of the Cymerus MSC manufacturing process over conventional processes, the potential therapeutic advantages shown here are particularly interesting as a putative treatment for post heart attack cardiac damage," he said.

The next steps

The study builds on previous work showing the efficacy of Cymerus MSCs in recovery from heart attack.

Once the data has been peer reviewed, the company will continue to work with relevant parties to determine the next steps for the use of the Cymerus treatment in heart attack recovery. Cynata will also look at the broader clinical development of the proprietary treatment.

Cynata Therapeutics is trading 1.44 per cent lower at $1.02.5 at 3:05 pm AEST.


Subscribe


CYP by the numbers
More From The Market Herald
EVE Investment (ASX:EVE) - Managing Director, Bill Fry - The Market Herald

" EVE Investments (ASX:EVE) increases revenue and cash balance in Q1 FY21

Wellness business EVE Investments (EVE) has announced a record start to FY21, increasing both its revenue and cash balance during the September quarter.
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald

" Holista CollTech’s (ASX:HCT) Path-Away kills 99.9pc of COVID-19

The coronavirus rollercoaster continues for small-cap biotech company Holista CollTech (HCT) today, with its share price almost doubling on the company’s latest announcement.
Imagion Biosystems (ASX:IBX) appoints Geoff Hollis as CFO

" Imagion Biosystems (ASX:IBX) appoints Geoff Hollis as CFO

Imagion Biosystems (IBX) has appointed Geoff Hollis as its new Chief Financial Officer (CFO).
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson - The Market Herald

" Anteris Technologies (ASX:AVR) one step closer to biologic heart valve

Anteris Technologies (AVR) is continuing to make progress in the development of its DurAVR 3D single-piece aortic valve.